JP2003522732A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522732A5 JP2003522732A5 JP2000589041A JP2000589041A JP2003522732A5 JP 2003522732 A5 JP2003522732 A5 JP 2003522732A5 JP 2000589041 A JP2000589041 A JP 2000589041A JP 2000589041 A JP2000589041 A JP 2000589041A JP 2003522732 A5 JP2003522732 A5 JP 2003522732A5
- Authority
- JP
- Japan
- Prior art keywords
- endothelin antagonist
- composition
- poly
- acetylglucosamine
- glucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002308 endothelin receptor antagonist Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 33
- -1 N-acetylglucosamine monosaccharides Chemical class 0.000 description 12
- 229960002442 glucosamine Drugs 0.000 description 12
- 229950006780 n-acetylglucosamine Drugs 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 231100001240 inorganic pollutant Toxicity 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/218,288 US6063911A (en) | 1993-12-01 | 1998-12-22 | Methods and compositions for treatment of cell proliferative disorders |
| US09/218,288 | 1998-12-22 | ||
| PCT/US1999/030575 WO2000036918A1 (en) | 1998-12-22 | 1999-12-21 | Methods and compositions for treatment of cell proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003522732A JP2003522732A (ja) | 2003-07-29 |
| JP2003522732A5 true JP2003522732A5 (enExample) | 2007-02-08 |
| JP4795539B2 JP4795539B2 (ja) | 2011-10-19 |
Family
ID=22814511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000589041A Expired - Lifetime JP4795539B2 (ja) | 1998-12-22 | 1999-12-21 | 細胞増殖性疾患を治療するための方法および組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6063911A (enExample) |
| EP (1) | EP1139752B1 (enExample) |
| JP (1) | JP4795539B2 (enExample) |
| CN (1) | CN100488512C (enExample) |
| AT (1) | ATE294504T1 (enExample) |
| AU (1) | AU780248B2 (enExample) |
| CA (1) | CA2356087C (enExample) |
| DE (1) | DE69925156T2 (enExample) |
| ES (1) | ES2242448T3 (enExample) |
| HK (1) | HK1043507B (enExample) |
| IL (2) | IL143700A0 (enExample) |
| NO (1) | NO330033B1 (enExample) |
| NZ (1) | NZ512586A (enExample) |
| WO (1) | WO2000036918A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| US6743783B1 (en) * | 1993-12-01 | 2004-06-01 | Marine Polymer Technologies, Inc. | Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| ID25921A (id) | 1997-04-28 | 2000-11-09 | Texas Biotechnology Corp | Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| IL150311A0 (en) | 1999-12-31 | 2002-12-01 | Texas Biotechnology Corp | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US20050245451A1 (en) * | 2000-04-05 | 2005-11-03 | Pincus Matthew R | Peptides selectively lethal to malignant and transformed mammalian cells |
| TWI306760B (en) * | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| PL366419A1 (en) * | 2000-08-22 | 2005-01-24 | Boehringer Ingelheim Pharma Bmbh & Co.Kg | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| US7041657B2 (en) | 2001-02-12 | 2006-05-09 | Marine Polymer Technologies Inc. | Compositions and methods for modulation of vascular structure and/or function |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| EP1587424A4 (en) * | 2002-12-31 | 2012-01-25 | Marinepolymer Tech Inc | Bleeding Compounds and their uses |
| KR20050098250A (ko) * | 2003-01-17 | 2005-10-11 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 에너골리틱제를 사용한 양성 전립선 비대증의 치료 방법 |
| NZ542501A (en) * | 2003-02-24 | 2009-09-25 | Marinepolymer Tech Inc | Compositions comprising chitin or chitosan and use thereof |
| WO2004100991A1 (en) * | 2003-05-15 | 2004-11-25 | Universite Catholique De Louvain | Use of endothelin-1 antagonists for improving cancer therapy |
| EP1673134A4 (en) * | 2003-09-12 | 2007-03-21 | Marinepolymer Tech Inc | RECEIVING VASCULAR ACCESS IN HEMODIALYSIS PATIENTS |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| EP1734821A4 (en) * | 2004-04-14 | 2011-07-06 | Uab Research Foundation | ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| JP5709356B2 (ja) | 2006-01-13 | 2015-04-30 | アメリカ合衆国 | 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子 |
| US8871247B2 (en) * | 2007-02-19 | 2014-10-28 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| AU2008269032B2 (en) | 2007-06-27 | 2013-12-05 | Novartis Ag | Complexes of IL-15 and IL-15Ralpha and uses thereof |
| US9539327B2 (en) * | 2007-11-26 | 2017-01-10 | The Research Foundation For The State University Of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| CA2796068C (en) | 2010-04-15 | 2022-07-19 | Marine Polymer Technologies, Inc. | Anti-bacterial applications of poly-n-acetylglucosamine nanofibers |
| MX356877B (es) | 2011-04-15 | 2018-06-19 | Marine Polymer Tech Inc | Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina. |
| GB201616087D0 (en) * | 2016-09-21 | 2016-11-02 | Tomalgae Cvba | Algae comprising therapeutic and/or nutritional agents |
| WO2019195851A1 (en) | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1038367A (en) * | 1963-05-28 | 1966-08-10 | Beecham Group Ltd | Penicillin derivatives |
| US3988411A (en) * | 1974-02-11 | 1976-10-26 | American Cyanamid Company | Spinning and shaping poly-(N-acetyl-D-glucosamine) |
| US3989535A (en) * | 1974-02-11 | 1976-11-02 | American Cyanamid Company | Solution of poly(N-acetyl-D-glucosamine) |
| JPS55152705A (en) * | 1979-05-18 | 1980-11-28 | Mitsubishi Rayon Co Ltd | Preparation of water-soluble alkali chitin |
| US4378017A (en) * | 1980-03-21 | 1983-03-29 | Kureha Kagaku Kogyo Kabushiki Kaisha | Composite material of de-N-acetylated chitin and fibrous collagen |
| JPS5927826A (ja) * | 1982-08-10 | 1984-02-14 | Masuko Suzuki | 抗感染症剤 |
| US4803168A (en) * | 1983-09-01 | 1989-02-07 | Damon Biotech, Inc. | Microencapsulation with polymers |
| US4749620A (en) * | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
| GR862353B (en) * | 1985-09-23 | 1987-01-19 | Lilly Co Eli | Anti-tumor method and compounds |
| JPS62288602A (ja) * | 1986-06-06 | 1987-12-15 | Agency Of Ind Science & Technol | キトサン変性物粒子の製造方法 |
| US4942129A (en) * | 1987-07-28 | 1990-07-17 | Queen's University At Kingston | Multiple membrane microencapsulation |
| US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
| US5071977A (en) * | 1989-05-10 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Plaque inhibiting oligosaccharide |
| US5116747A (en) * | 1989-08-11 | 1992-05-26 | University Of Waterloo | Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate |
| US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| JPH04334322A (ja) * | 1991-05-09 | 1992-11-20 | Unitika Ltd | 抗腫瘍剤 |
| US5382569A (en) * | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
| CA2072395A1 (en) * | 1991-07-01 | 1993-01-02 | John T. Hunt | Bicyclic endothelin analogues |
| US5219749A (en) * | 1991-10-09 | 1993-06-15 | Institute For Molecular Biology & Biotechnology/Forth | Process for isolating and preparing purified chitin deacetylase |
| US5229123A (en) * | 1991-10-09 | 1993-07-20 | Hoffmann-La Roche Inc. | Antifungal agents |
| WO1993009176A2 (en) * | 1991-10-29 | 1993-05-13 | Clover Consolidated, Limited | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
| ES2164054T3 (es) * | 1991-11-05 | 2002-02-16 | Smithkline Beecham Corp | Antagonistas de receptores de endotelina. |
| IL100096A (en) * | 1991-11-20 | 1996-03-31 | Univ Ramot | Method for entrapment of active materials in chitosan |
| US5260002A (en) * | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
| US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5550110A (en) * | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| WO1994003483A1 (en) * | 1992-07-30 | 1994-02-17 | Chiron Corporation | Endothelin receptor-binding compounds |
| TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| US5858350A (en) * | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| US5624679A (en) * | 1993-12-01 | 1997-04-29 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers |
| US5622834A (en) * | 1993-12-01 | 1997-04-22 | Marine Polymer Technologies, Inc. | Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
| WO1996011927A1 (en) * | 1994-10-12 | 1996-04-25 | Abbott Laboratories | Endothelin antagonists |
| TW313568B (enExample) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US5658943A (en) * | 1995-01-05 | 1997-08-19 | Warner-Lambert Company | Phenylalanine derivatives as endothelin antagonists |
| WO1996039122A1 (en) * | 1995-06-06 | 1996-12-12 | Marine Polymer Technologies, Inc. | POLY-β-1→4-N-ACETYLGLUCOSAMINE |
| AU6603996A (en) * | 1995-08-24 | 1997-03-19 | Warner-Lambert Company | Furanone endothelin antagonists |
| AU2529297A (en) * | 1996-04-10 | 1997-10-29 | Warner-Lambert Company | Ketoacid endothelin antagonists |
-
1998
- 1998-12-22 US US09/218,288 patent/US6063911A/en not_active Expired - Lifetime
-
1999
- 1999-12-21 CN CNB998163155A patent/CN100488512C/zh not_active Expired - Lifetime
- 1999-12-21 AT AT99968523T patent/ATE294504T1/de not_active IP Right Cessation
- 1999-12-21 JP JP2000589041A patent/JP4795539B2/ja not_active Expired - Lifetime
- 1999-12-21 EP EP99968523A patent/EP1139752B1/en not_active Expired - Lifetime
- 1999-12-21 IL IL14370099A patent/IL143700A0/xx active IP Right Grant
- 1999-12-21 NZ NZ512586A patent/NZ512586A/xx not_active IP Right Cessation
- 1999-12-21 HK HK02104737.8A patent/HK1043507B/zh not_active IP Right Cessation
- 1999-12-21 ES ES99968523T patent/ES2242448T3/es not_active Expired - Lifetime
- 1999-12-21 AU AU25919/00A patent/AU780248B2/en not_active Expired
- 1999-12-21 WO PCT/US1999/030575 patent/WO2000036918A1/en not_active Ceased
- 1999-12-21 CA CA002356087A patent/CA2356087C/en not_active Expired - Lifetime
- 1999-12-21 DE DE69925156T patent/DE69925156T2/de not_active Expired - Lifetime
-
2001
- 2001-06-12 IL IL143700A patent/IL143700A/en not_active IP Right Cessation
- 2001-06-20 NO NO20013071A patent/NO330033B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003522732A5 (enExample) | ||
| Mizumoto et al. | Interaction of chondroitin sulfate and dermatan sulfate from various biological sources with heparin-binding growth factors and cytokines | |
| JP2610792B2 (ja) | 多糖誘導体および薬物担体 | |
| US6063911A (en) | Methods and compositions for treatment of cell proliferative disorders | |
| JP2006502129A5 (enExample) | ||
| BR0113663A (pt) | Composições de pelìcula de pectina | |
| BR9914360A (pt) | N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5 | |
| WO1996002260A1 (en) | Wound healing agent | |
| JP2006513992A5 (enExample) | ||
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| CA2321461A1 (en) | Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents | |
| HU230385B1 (hu) | Részlegesen deszulfatált glükóz-amino-glükánok származékai mint a heparanáz enzim inhibitorai, előállításuk és alkalmazásuk, valamint ilyen származékokat tartalmazó gyógyszerkészítmények | |
| AUPQ879500A0 (en) | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease | |
| EP2298336A3 (en) | Promotion of epithelial regeneration | |
| BR9808008A (pt) | Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico. | |
| US20210393855A1 (en) | New hydrogels having a silylated structure, and method for obtaining same | |
| MXPA01009690A (es) | Moduladores de polisacaridos y usos de los mismos. | |
| ES2283585T3 (es) | Amilopectina hiperramificada para su utloizacion en procedimientos para el tratamiento quirurgico o terapeutico de mamiferos o en procedimientos de diagnostico, especialmente para su uso como extensor del volumen de plasma. | |
| JP2006347883A (ja) | 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物 | |
| Singh et al. | Chitosan hydrogel: Its applications in medicine and dentistry | |
| WO2001008708A3 (en) | Enhanced delivery via serpin enzyme complex receptor ligands | |
| BR9811422A (pt) | Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular | |
| JP3390836B2 (ja) | 線維芽細胞増殖因子に結合性を有するオリゴ糖及びその製造法 | |
| ES2347245T3 (es) | Peptidos fisiologicamente activos y farmacos que contienen los mismos. | |
| JP2004210714A5 (enExample) |